Username Password
About People & Picks | Help | Sign up
Home My P&P People Picks Tops Blogs Groups
S&P 500: 1,317.11 Change: -0.21%
Neurodoc
Neurodoc vip
P&P Score: 99.39   Points: 88.35   Accuracy: 47.75%   Average Pick Score: 0.31   Annual Return: 10.03% (36.16% since 10/18/08)  

Neurodoc's Blog : M&M boys up on healthy volume today

Date February 3, 2010    Comments Comments (4)    Rate this post Recommend This Post (78)   
Bookmark and Share
Abuse this post  Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
Share ThisShare This
Not Mantle and Maris but Medivation (MDVN) and Map Pharmaceuticals (MAPP) showed solid gains on healthy volume today. News today was that the phase 3 confirmatory trial for Dimebon for Alzheimer's disease, if positive (and a BIG but hopeful if!) could generate 2 bil revenue by 2015 and may be announced in Mar, although not official. This is grandslam v. strikeout. MAPP (see prior blogs) is more like a consistent singles .300 hitter.
Tags : MDVN   MAPP  

4 Comment(s):

Author MackTheKnife     Date February 3, 2010 02:41 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
Howdy, Neurodoc!

Not Mantle and Maris but Medivation (MDVN) and Map Pharmaceuticals (MAPP) showed solid gains on healthy volume today.

The New York Yankees! Biotechnology and pharmaceutical equities! These are a few of My Favorite Things (http://tinyurl.com/2kwnxm).

Thanks to you, I plan to conduct my research and analyses of both MDVN and MAPP with all due diligence during the next week or so.

Good luck!

MackTheKnife
Author Neurodoc     Date February 3, 2010 15:49 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
Thanks, Mack, let me know what you find. JW
Author rjm77me     Date February 9, 2010 10:29 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
It may be time to take half of the profit off the table - just by looking at chart. I do not know much about the fundamentals. You know better about the growth driver.
Or buy some protecion and let the profit run
Author Neurodoc     Date February 11, 2010 00:57 Abuse this post Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
The potential growth drivers are 1) Dimebon is potentially disease modifying, not just another symptomatic drug like Aricept, and 2) no other truly disease-modifying agents appear to be imminently available. Zacks analysis especially doesn't emphasize #1. I haven't bet the ranch (about 10% of my portfolio).
Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.
Sponsored Links
©2008-2012 PeopleAndPicks.com | Terms of Use